Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety of tofacitinib in Brazilian patients from Phase 2 (P2) and Phase 3 (P3) global studies of up to 24 months’ duration were evaluated. METHODS: Data were pooled from Brazilian p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lomonte, Andrea B.V., Radominski, Sebastião C., Marcolino, Flora M.D., Brenol, Claiton V., Zerbini, Cristiano A.F., García, Erika G., Akylbekova, Ermeg L., Rojo, Ricardo, de Leon, Dario Ponce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081087/
https://www.ncbi.nlm.nih.gov/pubmed/30075534
http://dx.doi.org/10.1097/MD.0000000000011609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081087/
https://www.ncbi.nlm.nih.gov/pubmed/30075534
http://dx.doi.org/10.1097/MD.0000000000011609

Ejemplares similares